In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of global readjustments being made at the parent companies’ level. The question for us: Will these restructured MNC pharma stocks – which have been underperforming for some time – make a comeback on the street? The answer depends on multiple factors – from how the sale proceeds were used, to whether, post-restructuring, the focus is on a 100% subsidiary. Either way, these stocks should be on your watchlist as news flow around them increases in the coming quarters.
